The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors

Overview

Journal Glob J Biochem

Date 2016 Dec 20

PMID 27990410

Citations 1

Authors

Yash R Somnay

Muthusamy Kunnimalaiyaan

Affiliations

Soon will be listed here.

Abstract

The phosphatidylinositol 3-kinase (PI3K)-Akt pathway is often aberrantly activated in neuroendocrine-derived cancers. Therefore, selectively targeting this pathway using small-molecule inhibitors may reduce neuroendocrine tumor burden, potentiate adjunct therapies, and achieve symptomatic control for patients with hormonally active and inoperable disease. Here, we discuss the role of the PI3K-Akt pathway in the malignant transformation of neuroendocrine tumors, specifically carcinoids and small cell lung cancers. The collective findings presented in this review propose that selective targeting of the PI3K-Akt pathway may mitigate neuroendocrine tumor progression, thus offering a viable therapeutic approach for managing systemic disease.

Citing Articles

Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.

Somnay Y, Simon K, Harrison A, Kunnimalaiyaan S, Chen H, Kunnimalaiyaan M Anticancer Drugs. 2012; 24(1):66-72.

PMID: 23147412 PMC: 3510354. DOI: 10.1097/CAD.0b013e3283584f75.

References

Zhou P, Jiang W, Zhang Y, Kahn S, Schieren I, Santella R . Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene. 1995; 11(3):571-80. View

Colakoglu T, Yildirim S, kayaselCuk F, Nursal T, Ezer A, Noyan T . Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?. Am J Surg. 2008; 195(6):719-25. DOI: 10.1016/j.amjsurg.2007.05.061. View

Sippel R, Carpenter J, Kunnimalaiyaan M, Lagerholm S, Chen H . Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol. 2003; 285(2):G245-54. DOI: 10.1152/ajpgi.00420.2002. View

Voortman J, Lee J, Killian J, Suuriniemi M, Wang Y, Lucchi M . Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A. 2010; 107(29):13040-5. PMC: 2919980. DOI: 10.1073/pnas.1008132107. View

Modlin I, Sandor A . An analysis of 8305 cases of carcinoid tumors. Cancer. 1997; 79(4):813-29. DOI: 10.1002/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2. View

Luo J, Manning B, Cantley L . Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003; 4(4):257-62. DOI: 10.1016/s1535-6108(03)00248-4. View

Kanamori Y, Kigawa J, Itamochi H, Shimada M, Takahashi M, Kamazawa S . Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res. 2001; 7(4):892-5. View

Tomassetti P, Migliori M, Corinaldesi R, Gullo L . Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther. 2000; 14(5):557-60. DOI: 10.1046/j.1365-2036.2000.00738.x. View

von Wichert G, Haeussler U, Greten F, Kliche S, Dralle H, Bohm B . Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells. Oncogene. 2004; 24(7):1284-9. DOI: 10.1038/sj.onc.1208264. View

10.

Moore S, Rintoul R, Walker T, Chilvers E, Haslett C, Sethi T . The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res. 1998; 58(22):5239-47. View

11.

Kunnimalaiyaan M, Ndiaye M, Chen H . Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery. 2006; 140(6):1009-14. DOI: 10.1016/j.surg.2006.06.040. View

12.

Tsurutani J, Castillo S, Brognard J, Granville C, Zhang C, Gills J . Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis. 2005; 26(7):1182-95. DOI: 10.1093/carcin/bgi072. View

13.

Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C . Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000; 11(9):1127-30. DOI: 10.1023/a:1008383132024. View

14.

Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon A, Caplin M . Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol. 2006; 18(5):355-60. DOI: 10.1111/j.1365-2826.2006.01425.x. View

15.

Kunnimalaiyaan M, Traeger K, Chen H . Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol. 2005; 289(4):G636-42. DOI: 10.1152/ajpgi.00146.2005. View

16.

Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L . The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. Ann Oncol. 2002; 12 Suppl 2:S105-9. DOI: 10.1093/annonc/12.suppl_2.s105. View

17.

Marte B, Downward J . PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci. 1997; 22(9):355-8. DOI: 10.1016/s0968-0004(97)01097-9. View

18.

Janson E, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E . Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997; 8(7):685-90. DOI: 10.1023/a:1008215730767. View

19.

Bjornsti M, Houghton P . The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 4(5):335-48. DOI: 10.1038/nrc1362. View

20.

Davis Z, MOERTEL C, MCILRATH D . The malignant carcinoid syndrome. Surg Gynecol Obstet. 1973; 137(4):637-44. View